HPV industrialization project

On May 18, 2020, the HPV industrialization base project of RecBio was started, with a total investment of nearly CNY 600 million and a total construction area of more than 100,000 square meters. The HPV vaccine series products of Jiangsu Rec-Biotechnology Co., Ltd. include: 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58), bivalent HPV16/18 vaccine and bivalent HPV6/11 vaccine, all of which are currently in clinical trials. Among them, the 9-valent HPV vaccine has entered phase III clinical trial.

At present, RecBio's 9-valent HPV vaccines have been successfully scaled up to a commercial scale of 100,000 doses in batch production and 5 million doses in annual production, with a very stable process. The 9-valent HPV vaccine has entered the phase III clinical trial, which is at the forefront in China.

The first phase of the project includes the 9-valent HPV vaccine production workshop and its supporting auxiliary facilities such as office, R & D, quality inspection, storage, and power facilities. After the completion of the project, the annual production capacity of 5 million doses of 9-valent HPV vaccine will be reached. The whole project is expected to start trial production in October 2023 and be formally put into operation in 2024, with sales revenue exceeding CNY 10 billion per year in 5 years.